NCT04779697CompletedPhase 1
GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight
Source: ClinicalTrials.gov · Last updated 10 Feb 2026
Brief summary (registry, in English)
To examine response to a glucagon-like peptide-1 analogue vs. placebo in patients with obesity and assess impact on craving, hunger, stress, and weight outcomes.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 96 (actual)
- First submitted
- 10 Feb 2021
- Start date
- 1 Feb 2021
- Primary completion date
- 19 Nov 2024
- Lead sponsor
- Yale University
- Diseases
- Obesity
- NCT number
- NCT04779697
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 96
- From 1 Feb 2021 to the primary completion date, 19 Nov 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current active participation in a weight loss program or weight loss of \>10% of total body weight during the prior 6 months
- Taking any other anti-obesity medication
Other illness
- Any significant current medical conditions, including neurological, renal, thyroid, cardiovascular, liver, endocrine or immune conditions, including diagnosis of T2DM or T1DM by American Diabetes Association (ADA) criteria
- Meet current or past DSM-IVR criteria for alcohol dependence or any substance use disorders, including nicotine, or psychiatric disorders, including eating disorders, or use of any psychiatric medications, including anxiolytics, antidepressants, naltrexone or antabuse, anti-smoking medications
- History of pancreatitis, medullary thyroid cancer, or MEN syndrome, or (6) women who are pregnant or lactating, or peri/postmenopausal
Who the study is looking for
- BMI ranging from 30-49.9 kg/m2
- No significant medical problems, including diabetes
- No history of HgbA1c \<6.5%
- English speaking and able to read English and complete study evaluations
- Able to provide informed written and verbal consent
Age in the registry: 18 years to 55 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Yale Stress Center: Yale University Coordinator of this site? Confirm its status | New Haven | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.